Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Modus Therapeutics Holding AB's selling, general, & admin. expense for the
three
months ended in Mar. 2026 was kr1.80 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr7.60 Mil.
Modus Therapeutics Holding AB (OSTO:MODTX) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Modus Therapeutics Holding AB Selling, General, & Admin. Expense Related Terms
Modus Therapeutics Holding AB Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modus Therapeutics Holding AB Selling, General, & Admin. Expense Chart
OSTO:MODTX vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Modus Therapeutics Holding AB's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modus Therapeutics Holding AB Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Modus Therapeutics Holding AB's Selling, General, & Admin. Expense falls into.
Modus Therapeutics Holding AB Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of kr7.60 Mil mean?
Modus Therapeutics Holding AB (OSTO:MODTX) has a Selling, General, & Admin. Expense of kr7.60 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Modus Therapeutics Holding AB and its competitors.
Is Modus Therapeutics Holding AB's Selling, General, & Admin. Expense too high?
Modus Therapeutics Holding AB's current Selling, General, & Admin. Expense is kr7.60 Mil. Overall, Modus Therapeutics Holding AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's Selling, General, & Admin. Expense compare to VRTX and REGN?
Modus Therapeutics Holding AB's Selling, General, & Admin. Expense of kr7.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Modus Therapeutics Holding AB and its competitors. Modus Therapeutics Holding AB's current Selling, General, & Admin. Expense is kr7.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current Selling, General, & Admin. Expense of kr7.60 Mil. The current Selling, General, & Admin. Expense is kr7.60 Mil. Modus Therapeutics Holding AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current Selling, General, & Admin. Expense is kr7.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
25GF Score
Get the complete analysis for OSTO:MODTX
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MODTX has been successfully added to your 
